Cholangiocarcinoma Clinical Trials (2026): 155 Recruiting Interventional Studies

Last updated: March 7, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Stage

First-Line (Treatment-Naive)

Standard first-line is now GemCis + durvalumab. These trials test additions or alternatives:

• IDH1-mutated: NCT06501625 - Ivosidenib + Durvalumab + GemCis
• HER2+:
  • NCT06178445 - GemCis + Trastuzumab + Pembrolizumab
  • NCT06282575 - Zanidatamab (HER2 bispecific) + SOC vs SOC (Phase 3)
• No specific mutation:
  • NCT07221253 - Rilvegostomig or Durvalumab + GemCis (Phase 3)
  • NCT05342194 - Toripalimab + Lenvatinib + GemCis
  • NCT05823311 - Lenvatinib + Tislelizumab + GemCis

Pretreated / Second-Line+

After progression on first-line therapy:

• FGFR2 fusion+:
  • NCT05727176 - Futibatinib (FDA-approved FGFR inhibitor)
  • NCT05948475 - Tinengotinib vs Physician's Choice (Phase 3)
  • NCT06728410 - Pemigatinib + Durvalumab (after GemCis+IO)
  • NCT06439485 - Pemigatinib + Atezolizumab + Bevacizumab
  • NCT06302621 - Pemigatinib + Afatinib (refractory)
• IDH1-mutated: NCT05876754 - Ivosidenib early access
• HER2+: NCT05150691 - DB-1303/BNT323 ADC
• Checkpoint inhibitor combos:
  • NCT05451043 - Durvalumab + Tremelimumab + Propranolol + Chemo
  • NCT06058663 - Radioembolization + Tremelimumab + Durvalumab
  • NCT05429697 - SMT-NK + Pembrolizumab (refractory to chemo)
  • NCT04298008 - AZD6738 + Durvalumab (after IO failure)
• CAR-T (CEA+):
  • NCT06010862 - CEA-targeted CAR-T
  • NCT06043466 - CEA CAR-T
  • NCT06126406 - CEA CAR-T
• ADC / Bispecific:
  • NCT06978114 - BL-B01D1 (EGFR×HER3 bispecific ADC) + PD-1
  • NCT05286814 - PDS01ADC + Hepatic Artery Infusion
  • NCT06529718 - Ivonescimab (PD-1/VEGF bispecific) vs FOLFOX
  • NCT07070700 - Cryoablation + Lenvatinib + QL1706 (bispecific)
• Other Phase 3:
  • NCT07265674 - Nanvuranlat vs Physician's Choice

Special Settings

• Neoadjuvant (before surgery):
  • NCT06341764 - Chemo + immunotherapy for locally advanced
  • NCT05967182 - GemCis + Pembrolizumab (high-risk resectable)
• Maintenance (after first-line response):
  • NCT06441747 - Durvalumab + Olaparib (after GemCis+Durvalumab)
  • NCT07260175 - Ivosidenib after adjuvant chemo (IDH1-mutated)

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.